Epigenomics AG operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Epigenomics AG with three other
pharmaceutical manufacturers in Europe:
sales of 2.46 million Euro [US$2.66 million]
Premier Veterinary Group PLC
of the United Kingdom
(£2.25 million [US$2.81 million]
of which 53%
was Buying group), and
based in Slovakia
(1.89 million Slovak Koruny [US$2.05 million]
of which 1,770%
Epigenomics AG reported sales of 2.08 million Euro (US$2.25 million)
December of 2015.
increase of 38.2%
versus 2014, when the company's sales were 1.51 million Euro.
Sales of Products Sales (Own and Third Party) saw an increase
that was more than double the company's growth rate: sales were up
88.6% in 2015, from
830,000.00 Euro to 1.57 million Euro.
Not all segments of Epigenomics AG experienced an increase in sales in 2015:
sales of Research and Development fell 35.0% to 361,000.00 Euro.